Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

@article{Storb2013GraftversushostDA,
  title={Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.},
  author={Rainer F Storb and Boglarka Gyurkocza and Barry E Storer and Mohamed L Sorror and Karl G. Blume and Dietger Niederwieser and Thomas R Chauncey and Michael A Pulsipher and Finn Bo Petersen and Firoozeh Sahebi and Edward D Agura and Parameswaran N. Hari and Benedetto Bruno and Peter A. Mcsweeney and Michael B. Maris and Richard T Maziarz and Amelia A. Langston and Wolfgang Andreas Bethge and Lars Lindhardt Vindel\ov and Georg-Nikolaus Franke and Ginna G. Laport and Andrew M. Yeager and Kai H{\"u}bel and H Joachim Deeg and George E Georges and Mary E D Flowers and Paul J Martin and Marco Mielcarek and Ann E. Woolfrey and David G Maloney and Brenda M Sandmaier},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 12},
  pages={1530-8}
}
PURPOSE We designed a minimal-intensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematologic malignancies unable to tolerate high-intensity regimens because of age, serious comorbidities, or previous high-dose HCT. The regimen allows the purest assessment of graft-versus-tumor (GVT) effects apart from conditioning and graft-versus-host disease (GVHD) not augmented by regimen-related toxicities. PATIENTS AND METHODS Patients… CONTINUE READING